LitAlert ~~ GeneLit.com

    • A step towards the ambition of precision oncology in recurrent ovarian cancer.
    • Wijaya ST, Tan DSP.
    • J Gynecol Oncol. 2022 Jul;33(4):e64. doi: 10.3802/jgo.2022.33.e64. Epub 2022 Jun 14.
    • Founder BRCA1 mutations in Nepalese population.
    • Mehta A, Diwan H, Gupta G, Nathany S, Agnihotri S, Dhanda S.
    • J Pathol Transl Med. 2022 Jun 15. doi: 10.4132/jptm.2022.05.02. Epub ahead of print.
    • Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratification.
    • Hollis RL, Meynert AM, Michie CO, Rye T, Churchman M, Hallas-Potts A, Croy I, McCluggage WG, Williams ARW, Bartos C, Iida Y, Okamoto A, Dougherty B, Barrett JC, March R, Matakidou A, Roxburgh P, Semple CA, Harkin DP, Kennedy R, Herrington CS, Gourley C.
    • Clin Cancer Res. 2022 Jun 13:clincanres.0368.2022-2-2 06:00:14.580. doi: 10.1158/1078-0432.CCR-22-0368. Epub ahead of print.
    • Association of BRCA1/2 mutations with prognosis and surgical cytoreduction outcomes in ovarian cancer patients: An updated meta-analysis.
    • Wang Y, Li N, Ren Y, Zhao J.
    • J Obstet Gynaecol Res. 2022 Jun 13. doi: 10.1111/jog.15326. Epub ahead of print.
    • Meta-Analysis
    • Case report: Response to platinum agents and poly (adenosine diphosphate-ribose) polymerase inhibitor in a patient with BRCA1 c.5096G>A (R1699Q) intermediate-risk variant.
    • Saito A, Tanioka M, Hirata M, Watanabe T, Odaka Y, Shimoi T, Sudo K, Noguchi E, Ishikawa M, Yonemori K.
    • Cancer Treat Res Commun. 2022 Jun 8;32:100587. doi: 10.1016/j.ctarc.2022.100587. Epub ahead of print.